- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.11. | BONYF: PerioCream becomes the most in-demand bonyf innovation | 2 | Euronext | ||
| 15.10. | bonyf AG receives the EU-MDR Certification Class IIa for PerioCream | 408 | Dow Jones News | DJ bonyf AG receives the EU-MDR Certification Class IIa for PerioCream
bonyf NV / Key word(s): Product Launch/Incoming Orders
bonyf AG receives the EU-MDR Certification Class IIa for PerioCream... ► Artikel lesen | |
| BONYF Aktie jetzt für 0€ handeln | |||||
| 15.09. | bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf | 388 | Dow Jones News | DJ bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf
bonyf NV / Key word(s): Conference/Corporate Action
bonyf NV Showcases Innovative Product Portfolio at ExpoPharm... ► Artikel lesen | |
| 05.09. | bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments | 300 | Dow Jones News | DJ bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments
bonyf NV / Key word(s): Financing/Corporate Action
bonyf NV Cancels Planned Capital Increase Following Positive... ► Artikel lesen | |
| 11.08. | Periocream: The Future Commercial Winner for bonyf | 406 | Dow Jones News | DJ Periocream: The Future Commercial Winner for bonyf
bonyf NV / Key word(s): Market Launch/Development of Sales
Periocream: The Future Commercial Winner for bonyf
11-Aug-2025 / 15:16 CET/CEST... ► Artikel lesen | |
| 14.07. | bonyf Reaffirms Its Long-Term Vision Amid Short-Term Market Volatility | 381 | Dow Jones News | DJ bonyf Reaffirms Its Long-Term Vision Amid Short-Term Market Volatility
bonyf NV / Key word(s): Corporate Action/Results Forecast
bonyf Reaffirms Its Long-Term Vision Amid Short-Term Market Volatility... ► Artikel lesen | |
| 30.06. | bonyf NV: Annual Results 2024 | 631 | Dow Jones News | DJ Annual Results 2024
bonyf NV / Key word(s): Annual Results/Financing
Annual Results 2024
30-Jun-2025 / 21:18 CET/CEST
=----------------------------------------------------------------------------------------------------------------------... ► Artikel lesen | |
| 03.06. | bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India | 441 | Dow Jones News | DJ bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India
bonyf NV / Key word(s): Capital Increase/Expansion
bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder... ► Artikel lesen | |
| 15.05. | bonyf NV Announces First Exports to the United States with Honest Pharma, Marking a Key Milestone in USA Growth Strategy | 587 | Dow Jones News | DJ bonyf NV Announces First Exports to the United States with Honest Pharma, Marking a Key Milestone in USA Growth Strategy
bonyf NV / Key word(s): Expansion/Market Launch
bonyf NV Announces First... ► Artikel lesen | |
| 08.04. | bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream | 381 | Dow Jones News | DJ bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream
bonyf NV / Key word(s): Research Update/Product Launch
bonyf Advances to Phase 3 in the Development of... ► Artikel lesen | |
| 13.03. | bonyf recently secures its EU Patent, US patent pending, for PerioTabs & PerioCream, launch in March 2025 at the IDS Cologne | 489 | Dow Jones News | DJ bonyf recently secures its EU Patent, US patent pending, for PerioTabs® & PerioCream, launch in March 2025 at the IDS Cologne
bonyf NV / Key word(s): Product Launch/Patent
bonyf recently secures... ► Artikel lesen | |
| 18.02. | bonyf Announces Plans for Dual Listing on Nasdaq and Euronext Paris with a Five-Step Strategy | 450 | Dow Jones News | DJ bonyf Announces Plans for Dual Listing on Nasdaq and Euronext Paris with a Five-Step Strategy
bonyf NV / Key word(s): Corporate Action/Funds
bonyf Announces Plans for Dual Listing on Nasdaq... ► Artikel lesen | |
| 30.01. | bonyf R&D presents its two latest innovations at IDS 2025 in Cologne | 985 | Dow Jones News | DJ bonyf R&D presents its two latest innovations at IDS 2025 in Cologne
bonyf NV / Key word(s): Product Launch/Market Launch
bonyf R&D presents its two latest innovations at IDS 2025 in Cologne... ► Artikel lesen | |
| 10.12.24 | bonyf and Honest Pharma are pleased to announce a Strategic Alliance to bring revolutionary oral care products to the US market | 463 | Dow Jones News | DJ bonyf and Honest Pharma are pleased to announce a Strategic Alliance to bring revolutionary oral care products to the US market
bonyf NV / Key word(s): Alliance/Investment
bonyf and Honest Pharma... ► Artikel lesen | |
| 09.12.24 | bonyf Achieves MDR Certification, Strengthening Commitment to Excellence in Oral Care Solutions | 569 | Dow Jones News | DJ bonyf Achieves MDR Certification, Strengthening Commitment to Excellence in Oral Care Solutions
bonyf NV / Key word(s): Regulatory Admission/Regulatory Approval
bonyf Achieves MDR Certification... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHTSPRING HEALTH SERVICES | 35,790 | 0,00 % | IPO Stock Of The Week: Health Care Leader BrightSpring Falls Back Into Buying Range | ||
| PROCEPT BIOROBOTICS | 35,860 | 0,00 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,550 | 0,00 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| PROGYNY | 24,020 | -0,54 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| GENEDX | 158,96 | 0,00 % | Cathie Wood's ARK sells Iridium, buys GeneDx and WeRide stock | ||
| BETA BIONICS | 29,380 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 43,390 | +1,64 % | EQS-PVR: Siemens Healthineers AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Siemens Healthineers AG
Siemens Healthineers AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
01.12.2025 /... ► Artikel lesen | |
| NUTEX HEALTH | 160,95 | 0,00 % | Nutex Health extends share repurchase plan | ||
| FRESENIUS MEDICAL CARE | 40,130 | +0,30 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| FRESENIUS | 48,130 | +0,25 % | DZ BANK stuft Fresenius SE auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Aktienwert für Fresenius nach den Anfang November vorgelegten Zahlen zum dritten Quartal von 56 auf 57 Euro angehoben. Die Einstufung wurde... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 9,310 | 0,00 % | Aveanna Healthcare stock price target raised to $13 by Raymond James | ||
| CERIBELL | 19,720 | +2,98 % | Ceribell Reports Third Quarter 2025 Financial Results | SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with... ► Artikel lesen | |
| GOODRX | 2,710 | 0,00 % | HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside? | ||
| CLEARPOINT NEURO | 13,540 | 0,00 % | Here's What Boosted ClearPoint Neuro (CLPT) in Q3 | ||
| ADAPTHEALTH | 9,420 | 0,00 % | AdaptHealth: Strategische Expansion und Technologie-Investitionen als Wachstumstreiber |
BONYF NV gehört der Branche Gesundheitswesen an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BONYF NV finden Sie auf Wallstreet Online.